Ebsteins anomaly of the tricuspid valve overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Template:Ebstein's anomaly of the tricuspid valve}}
{{Template:Ebsteins anomaly of the tricuspid valve}}


{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}}; Claudia P. Hochberg, M.D.; [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}}; Claudia P. Hochberg, M.D.; [[Priyamvada Singh|Priyamvada Singh, MBBS]] [mailto:psingh13579@gmail.com]

Revision as of 17:32, 16 November 2012

Ebsteins anomaly of the tricuspid valve Microchapters

Home

Patient Information

Overview

Historical Perpective

Classification

Pathophysiology

Causes

Differentiating Ebstein's Anomaly from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography

CT

MRI

Other Imaging Findings

Other diagnostic studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Ebsteins anomaly of the tricuspid valve overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ebsteins anomaly of the tricuspid valve overview

CDC on Ebsteins anomaly of the tricuspid valve overview

Ebsteins anomaly of the tricuspid valve overview in the news

Blogs on Ebsteins anomaly of the tricuspid valve overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]}; Claudia P. Hochberg, M.D.; Priyamvada Singh, MBBS [3]

Overview

Ebstein's anomaly is a congenital heart defect in which the opening of the tricuspid valve is displaced towards the apex of the right ventricle of the heart (congenital apical displacement of the tricuspid valve that typically causes significant tricuspid regurgitation).

Anatomy

The picture below shows displacement of tricuspid valve towards the apex of right ventricle with subsequent atrialization of a portion of the morphologic right ventricle:

Pathophysiology

The annulus of the valve is in normal position. The valve leaflets however, are to a varying degree attached to the walls and septum of the right ventricle. There is subsequent atrialization of a portion of the morphologic right ventricle (which is then contiguous with the right atrium). This causes the right atrium to be large and the anatomic right ventricle to be small in size. 50% of cases involve an atrial shunt (either a PFO or an ASD).

Epidemiology and Demographics

Ebstein's anomaly is a rare congenital heart disease (observed in 5/100,000 newborns in the United States) with no gender predilection, but a higher incidence in Caucasians.

Risk Factors

Administration of Lithium Carbonate or benzodiazepines during pregnancy is associated with a higher risk of Ebstein's anomaly.

Natural History, Complications, Prognosis

The symptoms of Ebstein's anomaly vary in severity, with some patients experiencing either no symptoms or very mild symptoms and others experiencing symptoms that may worsen over time such as (cyanosis), heart failure, heart block, or other tachyarrhythmias or bradyarrhythmias. Paradoxical embolization, brain abscesses and pulmonary embolism may also occur.

Diagnosis

Symptoms

The symptoms of Ebstein's anomaly depend upon the degree of apical displacement of the tricuspid valve leaflet as well as the degree of dysfunction of the tricuspid valve. If the tricuspid valve is severely deformed, fetal hydrops may occur. If the valve is functioning, patients may remain symptom free for many years.

Physical Examination

Ebstein's anomaly is characterized by tricuspid regurgitation and variable degrees a cyanosis depending upon the magnitude of right to left shunting. And elevation of the jugular venous pressure is often present.

Electrocardiography

The EKG is abnormal in 50 to 60% of patients, and will often show signs of right atrial enlargement, including "Himalayan" P waves which are P waves greater than 2.5 mm in height in leads 2, 3, and aVF. First-degree AV block, low QRS voltage, an atypical right bundle branch block, T wave inversions, and Wolff-Parkinson-White syndrome may also be present.

Chest X-Ray

The chest X Ray in Ebstein’s anomaly of the tricuspid valve may demonstrate cardiomegaly, a dilated right atrium and a pruned pulmonary vasculature.

Shown below is the chest x-ray of a patient with Ebstein's anomaly in whom the right atrium is markedly enlarged.

Magnetic Resonance Imaging

Magnetic resonance imaging can be helpful as a diagnostic tool in conditions where the echocardiographic findings are inconclusive.[1]

CT

Computed tomography can be helpful as a diagnostic tool in conditions where the echocardiographic findings are inconclusive.

Electrophysiologic Testing

Electrophysiologic testing may be done in Ebstein's anomaly patients who have rhythm disturbances such as tachyarrhythmias, or Wolff-Parkinson-White syndrome. An electrophysiology study helps in identifying accessory pathways prior to an ablation procedure.

Medical Therapy

Medical management of patients with Ebstein’s anomaly consists of supportive care such as:

Some Ebstein's anomaly patients present with an (antidromic) AV nodal reentrant tachycardia with associated pre-excitation. Among these patients, the preferred pharmacological treatment agent is procainamide. Since AV-blockade may promote conduction over the accessory pathway, drugs such as beta blockers, calcium channel blockers and digoxin are contraindicated.

If there is atrial fibrillation with pre-excitation, treatment options include procainamide, flecainide, propafenone, dofetilide and ibutilide since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical cardioversion. Intravenous amiodarone may also convert atrial fibrillation and/or slow the ventricular response.

Surgery

Tricuspid valve repair is indicated in patients in which there is symptoms or deteriorating exercise capacity, cyanosis (oxygen saturation less than 90%), paradoxical embolism, progressive cardiomegaly on chest x-ray or progressive right ventricular dilation or reduction of right ventricular systolic function. When possible, repair is favored over replacement.

Prevention

In so far as Lithium and benzodiazepines have been associated with an increased risk of Ebstein's anomaly, these drugs should be avoided if possible in the first trimester of pregnancy.

ACC / AHA 2008 Guidelines- Recommendation for Endocarditis Prophylaxis - Ebstein's anomaly of the Tricuspid Valve(DO NOT EDIT)[2]

Class IIa
"1.Antibiotic prophylaxis before dental procedures that involve manipulation of gingival tissue or the periapical region of the teeth or perforation of the oral mucosa is reasonable in cyanotic patients with Ebstein’s anomaly and postoperative patients with a prosthetic cardiac valve.(Level of Evidence: C) "

References

  1. Eustace S, Kruskal JB, Hartnell GG (1994). "Ebstein's anomaly presenting in adulthood: the role of cine magnetic resonance imaging in diagnosis". Clinical Radiology. 49 (10): 690–2. PMID 7955830. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  2. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.

Template:WH Template:WS